C
Crescent Biopharma, Inc.
CBIO · NASDAQ · Healthcare · 637M
Closing price
$14.91
+5.59% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
0.8×
Enterprise value / EBITDAEV/EBITDA
0.4×
Free cash flow yieldFCF yield
-93.0%
Return on equityROE
-75.8%
Operating margin
-1407.5%
Net debt / EBITDAbalance-sheet strength
1.4×
Interest coverage
-69.9×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.